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Abstract
The cJun NH2-terminal kinase (JNK) signal transduction pathway has been implicated in mammary carcinogenesis. To test
the role of JNK, we examined the effect of ablation of the Jnk1 and Jnk2 genes in a Trp53-dependent model of breast cancer
using BALB/c mice. We detected no defects in mammary gland development in virgin mice or during lactation and
involution in control studies of Jnk1
2/2 and Jnk2
2/2 mice. In a Trp53
2/+ genetic background, mammary carcinomas were
detected in 43% of control mice, 70% of Jnk1
2/2 mice, and 53% of Jnk2
2/2 mice. These data indicate that JNK1 and JNK2
are not essential for mammary carcinoma development in the Trp53
2/+ BALB/c model of breast cancer. In contrast, this
analysis suggests that JNK may partially contribute to tumor suppression. This conclusion is consistent with the finding that
tumor-free survival of JNK-deficient Trp53
2/+ mice was significantly reduced compared with control Trp53
2/+ mice. We
conclude that JNK1 and JNK2 can act as suppressors of mammary tumor development.
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Introduction
The cJun NH2-terminal kinase (JNK) group of signaling
enzymes are activated by cytokines/growth factors and also by
exposure to environmental stress [1]. Targets of the JNK pathway
include members of the activator protein 1 (AP1) group of
transcription factors (e.g. cJun, JunB, and JunD). JNK is therefore
a major regulatory mechanism of AP-1 dependent gene expression
[1]. In addition, JNK can regulate many cytoplasmic and nuclear
processes [2]. These studies have implicated the JNK signaling
pathway in the regulation of cell growth and cell death [1].
Dysregulation of the JNK pathway may therefore contribute to the
development of cancer [3].
The role of JNK in cancer has been studied using mouse models
that are JNK-deficient. Two genes (Jnk1 and Jnk2) encode isoforms
of JNK that are ubiquitously expressed [1]. Jnk1
2/2 mice and
Jnk2
2/2 mice are viable, but compound mutant Jnk1
2/2 Jnk2
2/2
mice exhibit an early embryonic lethal phenotype [1]. Studies using
Jnk1
2/2 mice and Jnk2
2/2 mice indicate that JNK may have
isoform-dependent effects on cancer. Thus, Bcr-Abl-induced
lymphoma [4] and carcinogen-induced hepatocellular carcinoma
[5] are suppressed in Jnk1
2/2 mice. Moreover, carcinogen-induced
skin cancer is suppressed in Jnk2
2/2 mice [6]. Similarly, important
roles for JNK2 have been identified in studies of human
glioblastoma, prostate cancer, and lung carcinoma cell lines
[7–10]. Together, these data confirm that both JNK1 and JNK2
can play roles in tumor development.
The purpose of this study was to test the requirement of JNK1
and JNK2 in a mouse model of mammary carcinoma. Somatic
mutation of the human p53 gene (TP53) is common in sporadic
breast cancer [11]. Furthermore, mammary carcinoma is the most
common form of cancer in women with heritable mutations in
TP53 (Li-Fraumeni syndrome) [12]. Initial studies using mouse
models demonstrated that Trp53
2/2 animals develop lymphoma
with high frequency and that Trp53
2/+ animals display a
moderately broader tumor spectrum with slower onset of disease
[13,14]. Subsequent studies using Trp53
2/+ mice on a BALB/c
strain background demonstrated that, like humans with Li-
Fraumeni syndrome, mammary carcinomas were frequently
observed, together with some lymphomas and sarcomas [15].
The BALB/c mouse model can therefore be used to examine
Trp53-dependent formation of mammary carcinoma.
We report that JNK1 and JNK2 are not required for the
development of mammary carcinoma in the Trp53
2/+ BALB/c
mouse model. In contrast, the tumor-free survival of JNK-deficient
Trp53
2/+ mice was reduced compared with control Trp53
2/+
mice. These data suggest that JNK may partially contribute to
tumor suppression.
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Mice
We have described Jnk1
2/2 mice [16] and Jnk2
2/2 mice [17]
on a C57BL/6J strain background [18], and mice with Trp53 gene
ablation [13] on a BALB/cMed strain background [19]. The mice
used in this study were backcrossed (ten generations) to the BALB/
cJ strain (Jackson Laboratories) and were housed in a facility
accredited by the American Association for Laboratory Animal
Care (AALAC). The Institutional Animal Care and Use
Committee (IACUC) of the University of Massachusetts Medical
School approved all studies using animals (Docket A-1032).
Genotype analysis
Genotype analysis was performed by PCR using genomic DNA
as the template. The wild-type Jnk1 (460 bp) and knockout Jnk1
(390 bp) alleles were identified using the amplimers 59-
CGCCAGTCCAAAATCAAGAATC-39,5 9-GCCATTCTGGT-
AGAGGAAGTTTCTC-39, and 59-CCAGCTCATTCCTCCA-
CTCATG-39. The wild-type Jnk2 (400 bp) and knockout Jnk2
(270 bp) alleles were identified using the amplimers 59- GGA-
GCCCGATAGTATCGAGTTACC-39,5 9-GTTAGACAATCC-
CAGAGGTTGTGTG-39, and 59-CCAGCTCATTCCTCCAC-
TCATG-39. The wild-type Trp53 (470 bp) and knockout Trp53
(700 bp) alleles were identified using the amplimers 59-TATACT-
CAGAGCCGGCCT-39,5 9-ACAGCGTGGTGGTACCTTAT-
39 and 59-CTATCAGGACATAGCGTTGG-39.
Analysis of tissue morphology
Mammary gland development was examined in virgin female
mice (8 to 10 weeks of age), lactating mice (1 week post partum),
and mice with mammary gland involution (pups removed at 1
week post-partum). The fourth inguinal mammary gland pair was
dissected from each mouse; one gland was analyzed by whole
mount and the other was formalin-fixed and paraffin-embedded.
Whole mounts were performed by spreading the gland on a
glass slide and incubation (2–4 hrs.) with Carnoy’s fixative (60%
ethanol, 30% chloroform, 10% glacial acetic acid). The glands
were then incubated with a graded series of 70%, 50% and 25%
ethanol (15 mins each), followed by 5 minutes in water and stained
with carmine alum overnight. The glands were washed in 70%,
90% and 100% ethanol (15 mins each), two changes of xylene
(30 mins), and then mounted with Permount (Fisher Scientific).
Analysisoftissuesectionswasperformed usingtissue fixedin10%
formalin for 24 h, dehydrated, and embedded in paraffin. Sections
(7 mm) were cut and stained using hematoxylin and eosin (Biocare
Medical). Immunofluorescence analysis was performed using de-
parafinized sections treated with the endogenous Biotin-Blocking kit
(Invitrogen), staining (4uC, 12 h) with biotin-conjugated anti-PCNA
(Invitrogen), and the incubation (25uC, 1 hr) with AlexaFluor633-
conjugated Streptavidin (Invitrogen). The sections on coverslips
were washed and mounted on slides using VectaShield medium
containing DAPI (Vector Labs.). Images were examined using a
Leica TCS SP2 confocal microscope.
Results
Effect of JNK-deficiency on mammary gland
development
We backcrossed Jnk1
2/2 mice [16] and Jnk2
2/2 mice [17] to
the BALB/cJ strain background. To test whether JNK-deficiency
altered mammary gland development, we examined Jnk1
2/2 and
Jnk2
2/2 BALB/c mice. No defects were detected in whole mount
preparations of fourth inguinal mammary glands of JNK-deficient
virgin female mice compared with control mice (Figure 1A).
Sections prepared from these mammary glands confirmed that
JNK-deficiency did not cause major defects in virgin mammary
gland development (Figure 1B).
Pregnancy causes major changes in mammary gland develop-
ment, including the formation of alveoli. Sections prepared from
the fourth inguinal mammary glands of JNK-deficient lactating
mice and control lactating mice were similar (Figure 2). Indeed,
sections stained for proliferating cell nuclear antigen (PCNA)
indicated that JNK-deficiency did not alter epithelial cell
proliferation in the lactating mammary gland (Figure 2).
Involution of the lactating mammary gland occurs after
weaning pups. We compared sections of the fourth inguinal
mammary glands prepared on day 2 and day 3 following weaning.
No defects in involution were detected in JNK-deficient mice
compared with control mice (Figure 3).
Together, these data demonstrate that JNK1-deficiency and
JNK2-deficiency did not cause detected changes in mammary
gland development. Similarly, no developmental defects caused by
JNK1-deficiency or JNK2-deficiency were detected in Trp53
2/+
mice.
Effect of JNK-deficiency on tumor development in
Trp53
2/2 BALB/c mice
We examined the tumor-free survival of Trp53
2/2 mice, Jnk1
2/2
Trp53
2/2 mice, and Jnk2
2/2 Trp53
2/2 mice on a BALB/c strain
background. The mice rapidly developed cancer and died
(Figure4A).Nosignificantdifferencesintumor-freesurvivalbetween
control and JNK-deficient mice were detected. Pathological
examinationofthe micedemonstrated,asexpected,ahighincidence
of lymphoma (Figure 4B). The second most frequent type of tumor
detected in Trp53
2/2 mice and Trp53
2/2 Jnk2
2/2 mice was
hemangiosarcoma (Figure 4B). In contrast, Jnk1
2/2 Trp53
2/2 mice
displayed fewer hemangiosarcomas and a higher incidence of
lymphoma compared with Trp53
2/2 mice (Figure 4B). These data
suggest that JNK1 may influence the tumor spectrum of Trp53
2/2
mice. Indeed, a low incidence of mammary carcinoma was observed
in both male and female Jnk1
2/2 Trp53
2/2 mice, but not in
Trp53
2/2 mice or Jnk2
2/2 Trp53
2/2 mice (Figure 4B). The
presence of mammary carcinoma in Jnk1
2/2 Trp53
2/2 mice
indicates that JNK may be relevant to breast cancer.
Effect of JNK-deficiency on tumor development in
Trp53
2/+ BALB/c mice
We performed studies of tumor-free survival of Trp53
2/+ mice,
Jnk1
2/2 Trp53
2/+ mice, and Jnk2
2/2 Trp53
2/+ mice on a
BALB/c strain background. Tumor development in the Trp53
2/+
mice was delayed compared with Trp53
2/2 mice (Figures 4 & 5).
Interestingly, JNK1-deficiency (p=0.026) and JNK2-deficiency
(p=0.012) caused significantly shortened tumor-free survival
compared with control Trp53
2/+ BALB/c mice (Figure 5A).
Pathological analysis demonstrated that mammary carcinoma was
the most common type of tumor detected. Mammary carcinomas
were detected in 43% of control mice, 70% of Jnk1
2/2 mice, and
53% of Jnk2
2/2 mice (Figure 5B). Analysis of mammary
carcinoma-free survival of Trp53
2/+ mice, Jnk1
2/2 Trp53
2/+
mice, and Jnk2
2/2 Trp53
2/+ mice demonstrated that JNK1-
deficiency (p=0.018) and JNK2-deficiency (p=0.039) significant-
ly decreased survival compared with control Trp53
2/+ mice
(Figure 5C). No significant difference in mammary carcinoma-free
survival between JNK1-deficient mice and JNK2-deficient mice
was detected (Figure 5C).
JNK and Breast Cancer
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Trp53
2/+ mice was associated with a decreased incidence of
hemangiosarcoma (Figure 5B). No hemangiosarcomas were
detected in JNK2-deficient Trp53
2/+ mice (Figure 5B). These
changes in tumor spectrum may reflect the shortened tumor-free
survival of Trp53
2/+ mice (Figure 5A,C).
Together, these data indicate that JNK1 and JNK2 are not
required for mammary carcinoma development in the Trp53
2/+
BALB/c mouse model of breast cancer. However, both JNK1 and
JNK2 can influence breast cancer development. It appears that
JNK can contribute to tumor suppression.
Discussion
JNK1 and JNK2 are not required for the development of
mammary carcinoma in the Trp53 BALB/c mouse model
JNK plays a critical role in the development of some forms of
cancer [1]. Thus, carcinogen-induced hepatocellular carcinoma
[5] and BcrAbl-induced lymphoma [4] are strongly suppressed in
Jnk1
2/2 mice and carcinogen-induced skin cancer is suppressed in
Jnk2
2/2 mice [6]. Moreover, studies of glioblastoma, prostate
cancer, and lung carcinoma cell lines have identified important
roles for JNK2 [7–10]. Together, these data confirm that JNK
plays an important role in cancer development.
The results of this study suggest that JNK may play a different
role in mammary carcinogenesis because neither JNK1-deficiency
nor JNK2-deficiency in the Trp53 BALB/c mouse model caused a
reduction in the incidence of mammary carcinoma. This
observation strongly contrasts with the finding that JNK-deficiency
can markedly suppress hepatocellular carcinoma, lymphoma, and
skin cancer [4–6].
Although JNK1-deficiency and JNK2-deficiency did not
suppress mammary carcinogenesis in the Trp53 BALB/c mouse
model, we cannot exclude the possibility that deficiency of both
JNK1 plus JNK2 might reduce the formation of mammary
carcinoma. Indeed, the Jnk1 and Jnk2 genes may have partially
redundant functions [18,20–22]. Studies of compound mutants
with disruption of Jnk1 plus Jnk2 are required. The early
embryonic lethal phenotype of Jnk1
2/2 Jnk2
2/2 mice [23] makes
such studies difficult. Nevertheless, the effect of compound JNK-
deficiency on mammary carcinoma development needs to be
tested in future studies.
Figure 1. Effect of JNK-deficiency in virgin mice on breast development. A) Whole mount preparations of the fourth inguinal mammary
gland of 10 week-old female virgin mice were stained with carmine red. Representative images are presented. Scale bar: 5 mm (upper panel); 800 mm
(lower panel). B) Sections of the breast tissue were stained with hematoxylin and eosin. Representative images are presented. Scale bar: 100 mm.
doi:10.1371/journal.pone.0012469.g001
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PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12469Figure 2. Effect of JNK-deficiency on breast development during lactation. Sections of the fourth inguinal mammary gland of female mice
at day 7 post-partum were examined by staining with hematoxylin and eosin (upper panels). Sections were also stained with an antibody to the
proliferation marker PCNA (red) and the DNA stain DAPI (blue) (lower panels). Scale bar: 200 mm( upper panel); 50 mm( lower panel).
doi:10.1371/journal.pone.0012469.g002
Figure 3. Effect of JNK-deficiency on mammary gland involution. The pups were removed from female mice at day 7 post-partum to induce
mammary gland involution. Sections of the fourth inguinal mammary gland were examined at two days or three days post-weaning by staining with
hematoxylin and eosin. Scale bar: 200 mm.
doi:10.1371/journal.pone.0012469.g003
JNK and Breast Cancer
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The analysis of JNK1-deficiency and JNK2-deficiency in the
Trp53 BALB/c mouse model of mammary carcinoma develop-
ment demonstrates that neither JNK1 nor JNK2 is required for
breast tumorigenesis (Figures 5). In contrast, the mammary
carcinoma-free survival of both Jnk1
2/2 mice and Jnk2
2/2 mice
was significantly reduced compared with control mice
(Figure 5C). These data suggest that JNK may have a tumor
suppressor role in breast cancer. This conclusion is consistent
with the observation that JNK2-deficiency increases breast
cancer in a transgenic mouse model with expression of polyoma
virus T antigen [24]. Moreover, human genetic analysis has
identified mutations in the JNK signaling pathway in breast
cancer that correlate with tumor suppression and metastasis [3].
Specifically, loss-of-function mutations in MKK4,ah u m a ng e n e
that encodes an activator of JNK, is mutated at low frequency in
human breast cancer [25,26,27,28]. It is likely that JNK1-
deficiency andJNK2-deficiency inthemousemay phenocopy the
effects of MKK4 gene mutation on breast cancer in humans. The
molecular mechanism of tumor suppression by the JNK signaling
pathway is unclear, but may be related to a requirement of JNK
for genetic stability [24]. Indeed, it has been reported that genes
that encode DNA repair enzymes are over-represented as targets
of JNK pathway signaling [29]. A role for JNK in the
maintenance of genetic stability is also consistent with the finding
that a dominant genetic trait in the Trp53
2/+ BALB/c mouse
model of mammary carcinogenesis is loss of heterozygosity at the
Trp53 locus [30]. This observation indicates that the formation of
mammary carcinoma in JNK-deficient mice may be caused by
accelerated loss of heterozygosity of tumor suppressor genes.
Figure 4. Effect of JNK-deficiency on Trp53
2/2 mouse survival. A) Kaplan-Meier analysis of the tumor-free survival of wild-type (WT),
Jnk1
2/2, Jnk2
2/2, Trp53
2/2, Jnk1
2/2 Trp53
2/2,a n dJnk2
2/2 Trp53
2/2 mice is presented. No statistically significant differences between Trp53
2/2,
Jnk1
2/2 Trp53
2/2,a n dJnk2
2/2 Trp53
2/2 mice were detected (Log-rank test, p.0.05). The data represent groups of 44–62 mice. These groups
include equal numbers of male and female mice. B) The spectrum of tumors detected in Trp53
2/2, Jnk1
2/2 Trp53
2/2,a n dJnk2
2/2 Trp53
2/2 mice
following euthanasia is presented. No statistically significant differences in the tumor profiles between genotypes were detected using Fisher’s
exact test.
doi:10.1371/journal.pone.0012469.g004
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2/+ mouse survival. A) Kaplan-Meier analysis of the tumor-free survival of wild-type (WT), Jnk1
2/2,
Jnk2
2/2, Trp53
2/+, Jnk1
2/2 Trp53
2/+, and Jnk2
2/2 Trp53
2/+ mice is presented. The survival of Jnk1
2/2 Trp53
2/+ mice and Jnk2
2/2 Trp53
2/+ mice was
reduced compared with Trp53
2/+ mice (Log-rank test, p=0.026 and 0.012, respectively). The data represent groups of 14 - 20 female mice. B) The
spectrum of tumors detected in Trp53
2/+, Jnk1
2/2 Trp53
2/+, and Jnk2
2/2 Trp53
2/+ female mice following euthanasia is presented. No statistically
significant differences in the tumor profiles between genotypes were detected using Fisher’s exact test. C) Kaplan-Meier analysis of the mammary
carcinoma-free survival of Trp53
2/+, Jnk1
2/2 Trp53
2/+, and Jnk2
2/2 Trp53
2/+ mice is presented. Cohorts of Trp53
2/+ mice (n=6), Jnk1
2/2 Trp53
2/+
mice (n=14), and Jnk2
2/2 Trp53
2/+ mice (n=8) with mammary carcinoma were examined. JNK1-deficiency and JNK2-deficiency caused reduced
mammary carcinoma-free survival compared with Trp53
2/+ mice (Log-rank test, p=0.018 and 0.039, respectively).
doi:10.1371/journal.pone.0012469.g005
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We tested the hypothesis that JNK1 or JNK2 plays a critical
role during breast cancer development. We found that neither
JNK1 nor JNK2 is required for mammary carcinoma in the Trp53
BALB/c mouse model. Breast tumor-free survival was significantly
reduced by JNK1-deficiency or JNK2-deficiency. These data
suggest that that JNK1 and JNK2 may play a role in mammary
carcinoma suppression.
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